Total Health
T

Review of the ASCEMBL Study: Asciminib vs. Bosutinib in CP-CML After ≥2 Prior TKIs

By Total Health FEATURING Tapan Kadia
By Total Health FEATURING Tapan Kadia
257 views
September 6, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
04:16
Luke Fletcher

Efficacy and Safety of Asciminib in Ph+ CML

50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
07:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …

Feat. E. Atallah
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
16:25
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

Feat. N. Cross
19:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML - Are We Doing It Right?

Feat. J. Cortés
17:30
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Rational TKI Choice in CML

Feat. M. Deininger
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
17:47
The University of Alabama at Birmingham School of Medicine

Treating CML Patients With TKI Resistance vs. TKI Intolerance

Feat. O. Jamy
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
27:47
City of Hope

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

Feat. I. Amanam
03:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatin…

Feat. E. Jabbour
08:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Tre…

Feat. D. Yeung
20:43
Indy Hematology Review

Controversies in the Management of CML in 2024

Feat. R. Larson
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
18:55
International CML Foundation

iCMLf Conversations: CML Clinical Highlights of EHA 2023

Feat. A. Hochhaus
06:26
Akriti Jain

Managing TKI AEs in CML: Thrombocytopenia, Hypertension, Pancreatic …

09:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatin…

Feat. J. Cortés